Final NICE guidance rejects Novartis's higher dose Glivec for GIST
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has today published final guidance rejecting Novartis's Glivec (imatinib) in higher doses for patients with unresectable and/or metastatic gastrointestinal stromal tumours (GIST) after standard doses have stopped working. According to the institute, there is not enough evidence to justify use of 600 or 800mg/day.